Santini, V., Almeida, A., Giagounidis, A., Gröpper, S., Jonasova, A., Vey, N., Mufti, G., Buckstein, R., Mittelman, M., Platzbecker, U., Shpilberg, O., Ram, R., del Canizo, C., Gattermann, N., Ozawa, K., Risueno, A., MacBeth, K., Zhong, J., Séguy, F., Hoenekopp, A., Beach, C., & Fenaux, P. (n.d.). 117 A PHASE 3 STUDY OF LENALIDOMIDE VERSUS PLACEBO IN RBC TRANSFUSION-DEPENDENT (TD) PATIENTS WITH LOWER-RISK MDS WITHOUT DEL(5Q) UNRESPONSIVE OR REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS). Leukemia research, 39(1), S60–S61. http://access.bl.uk/ark:/81055/vdc_100059913222.0x000001